MX2016000293A - Biomarcadores del trastrono del espectro autista. - Google Patents

Biomarcadores del trastrono del espectro autista.

Info

Publication number
MX2016000293A
MX2016000293A MX2016000293A MX2016000293A MX2016000293A MX 2016000293 A MX2016000293 A MX 2016000293A MX 2016000293 A MX2016000293 A MX 2016000293A MX 2016000293 A MX2016000293 A MX 2016000293A MX 2016000293 A MX2016000293 A MX 2016000293A
Authority
MX
Mexico
Prior art keywords
autism
metabolites
spectrum disorder
metabolic signatures
autism spectrum
Prior art date
Application number
MX2016000293A
Other languages
English (en)
Inventor
Alan Smith
Paul West
Robert E Burrier
Laura Egnash
Preeti Bais
Original Assignee
Stemina Biomarker Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stemina Biomarker Discovery Inc filed Critical Stemina Biomarker Discovery Inc
Publication of MX2016000293A publication Critical patent/MX2016000293A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/70—Machine learning, data mining or chemometrics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

En la presente se describen métodos para identificar improntas metabólicas en el plasma sanguíneo que son exclusivas del autismo. Las muestras son analizadas mediante diversas técnicas basadas en espectrometría de masas-cromatografía para medir ortogonalmente una amplia variedad de metabolitos de peso molecular pequeño producidos diferencialmente en muestras de pacientes autistas versus muestras de controles no autistas. Estos metabolitos individuales o un panel de los metabolitos sirven como improntas metabólicas del autismo. Las improntas metabólicas se utilizan en métodos diagnósticos para identificar con exactitud a los individuos que padecen de trastornos del espectro autista (TEA).
MX2016000293A 2013-07-09 2014-07-03 Biomarcadores del trastrono del espectro autista. MX2016000293A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361844128P 2013-07-09 2013-07-09
US201461996835P 2014-05-14 2014-05-14
PCT/US2014/045397 WO2015006160A2 (en) 2013-07-09 2014-07-03 Biomarkers of autism spectrum disorder

Publications (1)

Publication Number Publication Date
MX2016000293A true MX2016000293A (es) 2016-06-21

Family

ID=52280698

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016000293A MX2016000293A (es) 2013-07-09 2014-07-03 Biomarcadores del trastrono del espectro autista.

Country Status (6)

Country Link
US (2) US10060932B2 (es)
EP (1) EP3019624B1 (es)
JP (1) JP6763770B2 (es)
CA (1) CA2917483A1 (es)
MX (1) MX2016000293A (es)
WO (1) WO2015006160A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150294081A1 (en) 2014-04-11 2015-10-15 Synapdx Corporation Methods and systems for determining autism spectrum disorder risk
US20190178900A1 (en) * 2016-05-13 2019-06-13 Stemina Biomarker Discovery, Inc. Autism subsets
CN110944650B (zh) 2017-03-31 2022-03-04 轴向治疗公司 用于治疗和预防孤独症及相关障碍的肠选择性螯合剂
US12080432B1 (en) 2017-06-01 2024-09-03 The Regents Of The University Of Colorado Plasma metabolome as a predictor of biological aging
EP3746796A4 (en) * 2018-01-29 2021-12-22 Stemina Biomarker Discovery, Inc. DIAGNOSIS AND TREATMENT OF AUTISTIC SPECTRUM DISORDERS BASED ON METABOTYPES CONTAINING AN AMINE
CN109813912B (zh) * 2019-01-04 2021-12-28 深圳大学 一组血清差异蛋白组合在制备用于检测孤独症的试剂中的应用
CA3136303A1 (en) * 2019-04-05 2020-10-08 Arizona Board Of Regents On Behalf Of Arizona State University Diagnostic for childhood risk of autism spectrum disorder
CN113906296B (zh) * 2019-04-23 2024-11-15 中国医学科学院北京协和医院 基于机器学习的使用代谢物作为标记物的孤独症谱系障碍诊断方法和装置
WO2020223197A1 (en) * 2019-05-02 2020-11-05 Stemina Biomarker Discovery, Inc. Diagnosis and treatment of autism spectrum disorders associated with altered metabolic pathways
JP7564832B2 (ja) * 2019-06-06 2024-10-09 アイカーン スクール オブ メディシン アット マウント サイナイ 金属代謝の周期的変動に関連する生物学的障害の診断のためのシステムおよび方法
US20220146527A1 (en) * 2019-09-17 2022-05-12 Chang Gung University Method of creating characteristic profiles of mass spectra and identification model for analyzing and identifying features of microorganisms
US20240118291A1 (en) * 2019-10-11 2024-04-11 Stemina Biomarker Discovery, Inc. Diagnosis and treatment of autism spectrum disorders using altered ratios of metabolic concentrations
US20240369538A1 (en) * 2019-10-16 2024-11-07 Rene Anand Live Virus Vaccine Injury Risk
KR20230074216A (ko) * 2020-09-21 2023-05-26 몰레큘러 유 코포레이션 자폐 스펙트럼 장애의 진단 및 치료 방법
CN116547520A (zh) * 2020-09-21 2023-08-04 分子优公司 孤独症谱系障碍的诊断与治疗方法
JP7753359B2 (ja) * 2020-10-24 2025-10-14 ユニヴェルシテートスピタル バーゼル ヒト血漿中のリゼルギン酸ジエチルアミド（ｌｓｄ）及び２，３－ジヒドロ－３－ヒドロキシ－２－オキソリセルギド（ｏ－ｈ－ｌｓｄ）を定量化するための方法
EP4012414A1 (en) * 2020-12-11 2022-06-15 Stalicla S.A. Diagnosis of autism spectrum disorder phenotype 1
CN113125588B (zh) * 2021-03-17 2022-01-14 广东省农业科学院农业质量标准与监测技术研究所 一种代谢组学分析技术判别鸭屎香单丛茶时空分类的应用
KR102530345B1 (ko) * 2021-08-04 2023-05-10 단국대학교 천안캠퍼스 산학협력단 대사체 프로파일링을 이용한 자폐 스펙트럼 장애의 진단용 조성물 및 이를 포함하는 진단키트
JP2024134052A (ja) * 2023-03-20 2024-10-03 株式会社島津製作所 データ処理方法、データ処理装置およびプログラム

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686311A (en) * 1995-06-23 1997-11-11 The Children's Mercy Hospital Diagnosis of autism and treatment therefor
US6708064B2 (en) * 2000-02-24 2004-03-16 Ali R. Rezai Modulation of the brain to affect psychiatric disorders
US6365593B2 (en) 2000-04-12 2002-04-02 Repligen Corporation Methylxanthines in the diagnosis and treatment of autistic disorder
JP2003530130A (ja) 2000-04-14 2003-10-14 メタボロン インコーポレイテッド メタボロミクスを使用した薬物発見、疾患の処置、及び診断のための方法
US7329489B2 (en) 2000-04-14 2008-02-12 Matabolon, Inc. Methods for drug discovery, disease treatment, and diagnosis using metabolomics
US20080154332A1 (en) * 2001-12-24 2008-06-26 The Cleveland Clinic Foundation Modulation of the Brain to Affect Psychiatric Disorders and Functions
US8131473B1 (en) 2004-05-20 2012-03-06 Metabolon, Inc. Data analysis methods for locating entities of interest within large, multivariable datasets
GB0504096D0 (en) 2005-02-28 2005-04-06 Tipogen As Method
US7604948B2 (en) * 2005-05-05 2009-10-20 The Regents Of The University Of California Biomarkers for diagnosing an autism spectrum disorder
US20070023677A1 (en) * 2005-06-29 2007-02-01 Perkins Patrick D Multimode ionization source and method for screening molecules
US7433787B2 (en) 2005-08-08 2008-10-07 Metabolon, Inc. System, method, and computer program product using a database in a computing system to compile and compare metabolomic data obtained from a plurality of samples
US7949475B2 (en) 2005-08-08 2011-05-24 Metabolon Inc. System and method for analyzing metabolomic data
JP5496650B2 (ja) 2006-03-21 2014-05-21 メタボロン インコーポレイテッド サンプル内の個々の要素を識別及び定量化するために分光測定データを分析するシステム、方法及びコンピュータプログラム製品
US20110229883A1 (en) 2007-04-10 2011-09-22 Bernd Spur Biochemical Markers for Disease States and Genes for Identification of Biochemical Defects
JP5306345B2 (ja) * 2007-07-26 2013-10-02 フェノメノーム ディスカバリーズ インク 自閉症スペクトラム障害の診断、リスク評価、及びモニタリングを行うための方法
US9086425B2 (en) * 2007-08-29 2015-07-21 The Cleveland Clinic Foundation Carbamylated proteins and risk of cardiovascular disease
US7884318B2 (en) 2008-01-16 2011-02-08 Metabolon, Inc. Systems, methods, and computer-readable medium for determining composition of chemical constituents in a complex mixture
WO2010045180A1 (en) * 2008-10-13 2010-04-22 Metabolon, Inc. Biomarkers for inflammatory bowel disease and methods using the same
DK200970026A (en) 2009-06-12 2010-12-13 Alfa Laval Corp Ab A centrifugal separator
EP2309276A1 (en) * 2009-09-22 2011-04-13 One Way Liver Genomics, S.L. Method for the diagnosis of non-alcoholic steatohepatitis based on a metabolomic profile
US8703424B2 (en) * 2010-03-22 2014-04-22 Stemina Biomarker Discovery, Inc. Predicting human developmental toxicity of pharmaceuticals using human stem-like cells and metabolomics
CA2797787C (en) * 2010-04-29 2019-07-09 Wisconsin Alumni Research Foundation Metabolic biomarkers of autism
US8980548B2 (en) * 2010-05-19 2015-03-17 Metabolon, Inc. Methods and reagents for metabolomics and histology in a biological sample and a kit for the same
CN103229052A (zh) * 2010-07-28 2013-07-31 梅塔博隆公司 用于前列腺癌的生物标记及其使用方法
WO2013016700A1 (en) * 2011-07-27 2013-01-31 The Research Foundation Of State University Of New York Methods for generating predictive models for epithelial ovarian cancer and methods for identifying eoc
WO2013059234A1 (en) * 2011-10-18 2013-04-25 Metabolon, Inc. Biomarkers for amyotrophic lateral sclerosis and methods using the same
EP2788763A4 (en) * 2011-12-09 2015-10-07 Metabolon Inc BIOMARKERS FOR KIDNEY CANCER AND METHOD FOR USE THEREOF
EP2890808A4 (en) * 2012-08-29 2016-09-28 California Inst Of Techn DIAGNOSIS AND TREATMENT OF AUTISTICAL DISEASES
EP2897614A4 (en) 2012-09-21 2016-04-13 Univ Toronto CMPF AS A BIOMARKER FOR DIABETES AND RELATED METHODS
EP2914748B1 (en) * 2012-11-02 2019-03-13 Stemina Biomarker Discovery, Inc. Predicting human developmental toxicity of pharmaceuticals using human stem-like cells and metabolomic ratios
US9910047B2 (en) * 2013-01-31 2018-03-06 Metabolon, Inc. Biomarkers related to insulin resistance progression and methods using the same
US20150294081A1 (en) * 2014-04-11 2015-10-15 Synapdx Corporation Methods and systems for determining autism spectrum disorder risk
US9176113B1 (en) * 2014-04-11 2015-11-03 Synapdx Corporation Methods and systems for determining autism spectrum disorder risk

Also Published As

Publication number Publication date
US20160169915A1 (en) 2016-06-16
US20190072569A1 (en) 2019-03-07
JP2016530504A (ja) 2016-09-29
US11268966B2 (en) 2022-03-08
WO2015006160A3 (en) 2015-11-26
EP3019624A4 (en) 2017-01-11
US10060932B2 (en) 2018-08-28
EP3019624B1 (en) 2020-09-16
JP6763770B2 (ja) 2020-09-30
WO2015006160A2 (en) 2015-01-15
EP3019624A2 (en) 2016-05-18
CA2917483A1 (en) 2015-01-15

Similar Documents

Publication Publication Date Title
WO2015006160A3 (en) Biomarkers of autism spectrum disorder
AU2018260845A1 (en) Evaluation and treatment of bradykinin-mediated disorders
CA2878044C (en) Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies
EP3839510A3 (en) Blood-based biomarkers of tumor sensitivity to pd-1 antagonists
GB2519906A (en) Methods and systems for detecting biological components
CA2797787A1 (en) Metabolic biomarkers of autism
BR112017025097A2 (pt) método para quantificação espectrométrica de massa de analitos extraídos de um dispositivo de microamostragem
MX373957B (es) Un método in vitro para detectar un biomarcador de cáncer en un sujeto.
WO2015094995A3 (en) Gene signature biomarkers of tumor response to pd-1 antagonists
EP4450644A3 (en) Increasing dynamic range for identifying multiple epitopes in cells
BR112015019326A2 (pt) dispositivo de registro de amostragem e armazenamento para análise de gás respiratório
EP4220170A3 (en) Method for detecting a solid tumor cancer
IN2014MN02101A (es)
MX360236B (es) Uso de marcadores en el diagnostico y tratamiento de cancer de prostata.
EA201790769A1 (ru) Определение уровней гликозаминогликанов методом масс-спектрометрии
BR112016024730A2 (pt) dispositivo, método e conjunto de análise imunocromatográfica
MX360479B (es) Anticuerpos contra microbioma, factores de estres y marcadores de mastocitos como marcadores de diagnostico para ibs.
WO2015077382A3 (en) Combined cytology and molecular testing for early detection of esophageal adenocarcinoma
BR112018010764A2 (pt) método para detectar atividade bacteriana em uma amostra biológica e unidade de detecção correspondente
EP4290231A3 (en) Method for assessing performance of an instrument with liquid chromatography and mass spectrometry functionalities
HK1204061A1 (en) Methods and kits for detecting and diagnosing neurotrauma
GB201102693D0 (en) Method for identifying neonates at risk for necrotizing enterocolitis
CY1121406T1 (el) Διαγνωση καρδιακης ανεπαρκειας
WO2016118920A3 (en) Metabolomic based biomarkers for colon cancer detection
EA201691168A1 (ru) Способы исследования бета-глюкана